Improved synthesis of the bifunctional chelator p-SCN-Bn-HOPO.

@article{Bhupathiraju2019ImprovedSO,
  title={Improved synthesis of the bifunctional chelator p-SCN-Bn-HOPO.},
  author={N. V. S. Dinesh K. Bhupathiraju and Ali Younes and Minhua Cao and Jafar Sunga Ali and Huseyin T. Cicek and Kathryn M Tully and Shashikanth Ponnala and John W. Babich and Melissa A Deri and Jason S. Lewis and Lynn C. Francesconi and Charles Michael Drain},
  journal={Organic \& biomolecular chemistry},
  year={2019}
}
The bifunctional ligand p-SCN-Bn-HOPO, which has four 1,2-hydroxypyridinone groups on a spermine backbone with an isothiocyanate linker, has been shown to be an efficient and stable chelator for Zr(iv) and, more importantly, the radioisotope 89Zr for use in radiolabeling antibodies for positron emission tomography (PET) imaging. Previous studies of 89Zr-HOPO-trastuzumab in mice showed low background, good tumor to organ contrast, and very low bone uptake which show p-SCN-Bn-HOPO to be an… 

The Race for Hydroxamate-Based Zirconium-89 Chelators

The progress in this research field until end of 2020 is described, including promising examples of new candidates of chelators currently in advanced stages for clinical translation that outrun the performance of the current gold standard DFO.

Side-by-Side Comparison of Five Chelators for 89Zr-Labeling of Biomolecules: Investigation of Chemical/Radiochemical Properties and Complex Stability

Five different chelating agents, namely DFO, CTH-36, DFO*, 3,4,3-(LI-1,2-HOPO) and DOTA-GA, were compared with regard to the relative kinetic inertness of their corresponding 89Zr complexes to evaluate their potential for in vivo application and stable 89ZR complexation.

Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical 89Zr-immuno-PET

DFO* is a superior candidate for preclinical and clinical 89Zr-immuno-PET reagents and provides superior detection of tumour-specific signal over the DFO conjugates in the intratibial BT-474 bone metastasis model.

Hydroxypyridinones as a Very Promising Platform for Targeted Diagnostic and Therapeutic Radiopharmaceuticals

HOPO multidentate bifunctional chelators are expected to be a very promising platform for building novel targeted radiometal-based diagnostic and therapeutic radiopharmaceuticals.

State of the Art in Radiolabeling of Antibodies with Common and Uncommon Radiometals for Preclinical and Clinical Immuno-PET

This review presents a state of the art overview of the practical aspects of radiolabeling of antibodies, ranging from fast kinetic affibodies and nanobodies to slow kinetic intact mAbs.

References

SHOWING 1-10 OF 14 REFERENCES

p-SCN-Bn-HOPO: A Superior Bifunctional Chelator for (89)Zr ImmunoPET.

In vivo studies demonstrate the successful use of (89)Zr-HOPO-trastuzumab to image BT474 breast cancer with low background, good tumor to organ contrast, and, importantly, very low bone uptake.

Macrocycle-Based Hydroxamate Ligands for Complexation and Immunoconjugation of 89Zirconium for Positron Emission Tomography (PET) Imaging.

Positron imaging and biodistribution studies in mice showed that 89 Zr-L4 had similar pharmacokinetic behavior to that of 89Zr-DFO, with rapid renal elimination and low residual activity in background tissues, and a high tumor specificity that was comparable to the performance of 89 zirconium desferrioxamine B-trastuzumab.

Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for 89Zr-immuno-PET

A bifunctional isothiocyanate variant of the octadentate chelator DFO* is reported, a candidate successor of DFO for future clinical 89Zr-immuno-PET studies and shows superior in vitro stability and in vivo performance when compared to 89 Zr-DFO-trastuzumab.

Novel Bifunctional Cyclic Chelator for 89Zr Labeling–Radiolabeling and Targeting Properties of RGD Conjugates

Findings indicate that FSC is a highly promising chelator for the development of 89Zr-based PET imaging agents.

Alternative Chelator for 89Zr Radiopharmaceuticals: Radiolabeling and Evaluation of 3,4,3-(LI-1,2-HOPO)

HOPO has the potential to replace DFO as the chelator of choice for 89Zr-based PET imaging agents and lead to a safer PET tracer with reduced background radiation dose.

Rational design, synthesis, and evaluation of tetrahydroxamic acid chelators for stable complexation of zirconium(IV).

A series of tetrahydroxamic acids of varying geometries are designed for improved complexation of (89) Zr, with the best chelators providing dramatically improved stabilities compared with the reference DFB.

Recent Advances in Zirconium-89 Chelator Development

This review focuses on recent advances in zirconium-89 chelation chemistry and will highlight the rapidly expanding ligand classes that are under investigation as DFO alternatives.

Direct comparison of the in vitro and in vivo stability of DFO, DFO* and DFOcyclo* for 89Zr-immunoPET

A novel chelator DFOcyclo*, a preorganized extended DFO derivative that enables octacoordination of the 89Zr radiometal is reported, which is a candidate to become the new clinically used standard chelator for immunoPET.

An octadentate bifunctional chelating agent for the development of stable zirconium-89 based molecular imaging probes.

The first octadentate bifunctional chelating agent for the development of (89)Zr-labelled (bio)conjugates with improved stability is reported, which is likely to help improve the stability of radiometal complexes in vivo.